Zydus Cadila gets tentative approval from USFDA for Abacavir and Lamivudine Tablets

08 Aug 2017 Evaluate

Zydus Cadila has received the tentative approval from the United States Food & Drug Administration (USFDA) to market Abacavir and Lamivudine Tablets USP, 600 mg/300 mg. The drug is indicated for use in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection and will be produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad.

The sales of Abacavir and Lamivudine Tablets is estimated at $240.2 million. The group now has more than 130 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. 

Zydus Lifesciences Share Price

893.45 11.50 (1.30%)
27-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1639.30
Dr. Reddys Lab 1240.00
Cipla 1312.85
Zydus Lifesciences 893.45
Lupin 2147.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×